Latest Human Genome Sciences Stories

2009-02-19 07:00:00

ROCKVILLE, Md., Feb. 19 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call to discuss its financial results for the year ended December 31, 2008.

2009-02-02 05:00:00

- Delivery of 20,000 doses of ABthrax will bring at least $150 million in revenue to HGS - ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.

2009-01-12 06:23:00

- Albuferon(R) for hepatitis C, LymphoStat-B(R) for lupus and ABthrax(R) for inhalation anthrax all progressing rapidly toward commercialization - - GSK Phase 3 trial of darapladib underway in chronic coronary heart disease - - HGS provides 2009 financial guidance; expects less than $25 million net cash burn - ROCKVILLE, Md., Jan.

2009-01-12 06:00:00

- Trial conducted by Novartis to evaluate safety and efficacy of Albuferon administered every four weeks in combination with ribavirin in patients with genotypes 2 and 3 hepatitis C - ROCKVILLE, Md., Jan. 12 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.

2009-01-09 15:00:00

ROCKVILLE, Md., Jan. 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.

2008-12-08 06:00:00

- Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) in the ACHIEVE 2/3 trial in patients with genotypes 2 and 3 chronic hepatitis C - - Patients receiving 900-mcg Albuferon had comparable rates of serious adverse events, severe adverse events and discontinuations due to adverse events, vs.

2008-09-02 18:00:07

ROCKVILLE, Md., Sept. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.

2008-08-29 06:00:55

Human Genome Sciences has completed enrollment and initial dosing in Bliss-76, the second of two pivotal Phase III randomized clinical trials of LymphoStat-B in patients with active systemic lupus erythematosus.

Word of the Day
  • Growing in low tufty patches.
The word 'cespitose' comes from a Latin word meaning 'turf'.